摘要
目的探讨吡柔比星(pirarubicin,THP)、表柔比星(epirubicin,EPI)两种不同药物膀胱灌注化疗,预防膀胱癌术后复发的疗效和安全性。方法对42例行膀胱癌手术后患者,随机分为2组:Ⅰ组THP(24例)、Ⅱ组EPI(18例),分别于术后1～2周开始规律膀胱灌注,比较2组肿瘤复发率。结果随访14～24个月,平均20个月;Ⅰ组和Ⅱ组2年复发率分别为16.67%、22.22%,2组比较统计学无差异(P>0.05)。Ⅰ组和Ⅱ组不良反应发生率分别为25.00%和61.11%,两组比较统计学有差异(P<0.05)。结论THP、EPI膀胱灌注预防膀胱癌术后复发疗效满意,不良反应轻,耐受性良好。
Objective To compare the therapeutic effect and safety of pirarubicin（THP）, Epirubicin （EPI） by bladder instillation after operation of bladder cancer. Methods patients with bladder cancer after operation were divided into two groups randomly. THP by bladder instillation was used in the first group （24 patients） , EPI in the second group （ 18 patients）. One or two weeks after the operation , bladder instillation was performed on all patients regularly. Then the tumor recurrent rates were compared among the two groups , and the effects were observed. Results All patients were followed up for 14- 24 months , the mean being 20 months. The tumor recurrent rates in the THP group , EPI group were 16. 67 % （4/24） , 22. 22 % （4/18） , respectively , without any significant difference observed （ P 〉 0. 05 ）. The side effect rates were 25.00% , 61.11% for groups Ⅰ and Ⅱ , respectively. The side effect rate of group Ⅱ was significantly higher than that of groups Ⅰ （ P 〈 0. 05）. Conclusion The THP and EPI groups had better therapeutic and tolerant effect , but fewer side effects.
出处
《中国实用医药》
2009年第31期32-33,共2页
China Practical Medicine
关键词
膀胱癌
吡柔比星
表柔比星
Bladder cancer
Pirarubicin
Epirubicin
